FindTrial
Sign In

Screening and clinical application of serum exosomes microRNA in patients with drug-induced liver injury

Screening and clinical application of serum exosomes microRNA in patients with drug-induced liver injury

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800018054
Enrollment
Unknown
Registered
2018-08-28
Start date
2019-01-01
Completion date
Unknown
Last updated
2018-09-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

drug-induced liver injury

Interventions

Control group:Health population
Case group:Drug-induced liver injury, viral hepatitis, autoimmune liver disease, nonalcoholic steatohepatitis

Sponsors

Shanghai Public Health Clinical Center Affiliated to Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. The occurrence of liver injury during medication conforms to the clinical diagnosis of drug-induced liver injury, and the RUCAM causality evaluation scale is greater than or equal to 8 points; 2. Aged 18-65 years old.

Exclusion criteria

Exclusion criteria: 1. Infected persons with hepatitis a virus (HAV), hepatitis b virus (HBV), hepatitis c virus (HCV), hepatitis d virus (HDV), hepatitis e virus (HEV) or human immunodeficiency virus (HIV); 2. Patients with non-alcoholic fatty liver disease (NAFLD), alcoholic liver disease (ALD), autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC), genetic metabolic liver disease and cardiovascular and cerebrovascular diseases; 3. Alpha fetoprotein > 100ng/ml, or imaging diagnosis of hepatocellular tumor.

Design outcomes

Primary

MeasureTime frame
serum exosomes microRNA;—

Contacts

Public ContactLi Li

Shanghai Public Health Clinical Center Affiliated to Fudan University

lilyshz@163.com+86 13524854583

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026